Boston Scientific Free Cash Flow 2010-2025 | BSX
Boston Scientific annual/quarterly free cash flow history and growth rate from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Boston Scientific free cash flow for the quarter ending March 31, 2025 was 354.00, a year-over-year.
- Boston Scientific free cash flow for the twelve months ending March 31, 2025 was , a year-over-year.
- Boston Scientific annual free cash flow for 2024 was $2.648B, a 47.44% increase from 2023.
- Boston Scientific annual free cash flow for 2023 was $1.796B, a 89.05% increase from 2022.
- Boston Scientific annual free cash flow for 2022 was $0.95B, a 28.57% decline from 2021.
| Boston Scientific Annual Free Cash Flow | |
|---|---|
| 2024 | 2,648.00 |
| 2023 | 1,796.00 |
| 2022 | 950.00 |
| 2021 | 1,330.00 |
| 2020 | 1,144.00 |
| 2019 | 1,382.00 |
| 2018 | 8.00 |
| 2017 | 1,107.00 |
| 2016 | 835.00 |
| 2015 | 444.00 |
| 2014 | 1,010.00 |
| 2013 | 918.00 |
| 2012 | 1,070.00 |
| 2011 | 720.00 |
| 2010 | 58.00 |
| 2009 | 528.00 |
| Boston Scientific Quarterly Free Cash Flow | |
|---|---|
| 2025-03-31 | 354.00 |
| 2024-12-31 | 2,648.00 |
| 2024-09-30 | 1,467.00 |
| 2024-06-30 | 644.00 |
| 2024-03-31 | -15.00 |
| 2023-12-31 | 1,796.00 |
| 2023-09-30 | 1,106.00 |
| 2023-06-30 | 597.00 |
| 2023-03-31 | 82.00 |
| 2022-12-31 | 950.00 |
| 2022-09-30 | 353.00 |
| 2022-06-30 | 32.00 |
| 2022-03-31 | -171.00 |
| 2021-12-31 | 1,330.00 |
| 2021-09-30 | 1,114.00 |
| 2021-06-30 | 753.00 |
| 2021-03-31 | 213.00 |
| 2020-12-31 | 1,144.00 |
| 2020-09-30 | 624.00 |
| 2020-06-30 | 28.00 |
| 2020-03-31 | -174.00 |
| 2019-12-31 | 1,382.00 |
| 2019-09-30 | 874.00 |
| 2019-06-30 | 490.00 |
| 2019-03-31 | 289.00 |
| 2018-12-31 | 8.00 |
| 2018-09-30 | 81.00 |
| 2018-06-30 | -344.00 |
| 2018-03-31 | 133.00 |
| 2017-12-31 | 1,107.00 |
| 2017-09-30 | 502.00 |
| 2017-06-30 | 110.00 |
| 2017-03-31 | -119.00 |
| 2016-12-31 | 835.00 |
| 2016-09-30 | 326.00 |
| 2016-06-30 | 428.00 |
| 2016-03-31 | 86.00 |
| 2015-12-31 | 444.00 |
| 2015-09-30 | 109.00 |
| 2015-06-30 | -229.00 |
| 2015-03-31 | -243.00 |
| 2014-12-31 | 1,010.00 |
| 2014-09-30 | 649.00 |
| 2014-06-30 | 359.00 |
| 2014-03-31 | 139.00 |
| 2013-12-31 | 918.00 |
| 2013-09-30 | 727.00 |
| 2013-06-30 | 533.00 |
| 2013-03-31 | 187.00 |
| 2012-12-31 | 1,070.00 |
| 2012-09-30 | 727.00 |
| 2012-06-30 | 501.00 |
| 2012-03-31 | 146.00 |
| 2011-12-31 | 720.00 |
| 2011-09-30 | 438.00 |
| 2011-06-30 | 141.00 |
| 2011-03-31 | -166.00 |
| 2010-12-31 | 58.00 |
| 2010-09-30 | -333.00 |
| 2010-06-30 | -129.00 |
| 2010-03-31 | -354.00 |
| 2009-12-31 | 528.00 |
| 2009-09-30 | 939.00 |
| 2009-06-30 | 546.00 |
| 2009-03-31 | 201.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $154.721B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.564B | 27.96 |
| Stryker (SYK) | United States | $149.011B | 31.16 |
| EssilorLuxottica (ESLOY) | France | $125.383B | 0.00 |
| Medtronic (MDT) | Ireland | $110.530B | 15.67 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.919B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.856B | 26.72 |
| ResMed (RMD) | United States | $37.567B | 28.22 |
| GE HealthCare Technologies (GEHC) | United States | $34.277B | 16.27 |
| Agilent Technologies (A) | United States | $33.923B | 22.11 |
| Terumo (TRUMY) | Japan | $27.568B | 35.81 |
| Koninklijke Philips (PHG) | Netherlands | $23.187B | 16.27 |
| Insulet (PODD) | United States | $21.804B | 85.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.151B | 11.66 |
| Baxter (BAX) | United States | $15.652B | 11.69 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.231B | 0.00 |
| Demant (WILYY) | Denmark | $9.110B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.625B | 23.06 |
| Lantheus Holdings (LNTH) | United States | $5.586B | 14.09 |
| Prestige Consumer Healthcare (PBH) | United States | $4.010B | 17.91 |
| Perrigo (PRGO) | Ireland | $3.653B | 9.26 |
| Haemonetics (HAE) | United States | $3.592B | 16.36 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.330B | 27.68 |
| ICU Medical (ICUI) | United States | $3.216B | 23.72 |
| GN Store Nord (GNNDY) | Denmark | $2.307B | 19.11 |
| QuidelOrtho (QDEL) | United States | $1.941B | 13.35 |
| LeMaitre Vascular (LMAT) | United States | $1.862B | 41.62 |
| AtriCure (ATRC) | United States | $1.628B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.271B | 12.90 |
| Acuren (TIC) | United States | $1.252B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.120B | 25.19 |
| Neogen (NEOG) | United States | $1.040B | 13.31 |
| BioLife Solutions (BLFS) | United States | $1.020B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.018B | 13.02 |
| Kestra Medical Technologies (KMTS) | United States | $0.919B | 0.00 |
| InMode (INMD) | Israel | $0.889B | 8.96 |
| CeriBell (CBLL) | United States | $0.697B | 0.00 |
| Owens & Minor (OMI) | United States | $0.644B | 5.34 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.606B | 0.00 |
| Evolus (EOLS) | United States | $0.600B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.551B | 0.00 |
| Valneva SE (VALN) | France | $0.489B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.465B | 0.00 |
| Surmodics (SRDX) | United States | $0.416B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.415B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.352B | 12.94 |
| SNDL (SNDL) | Canada | $0.328B | 0.00 |
| Quanterix (QTRX) | United States | $0.328B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.301B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.283B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.273B | 23.03 |
| Cerus (CERS) | United States | $0.260B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.252B | 0.00 |
| ZimVie (ZIMV) | United States | $0.251B | 11.39 |
| Cresco Labs (CRLBF) | United States | $0.250B | 0.00 |
| Brainsway (BWAY) | Israel | $0.248B | 65.50 |
| Aurora Cannabis (ACB) | Canada | $0.239B | 71.00 |
| Biote (BTMD) | United States | $0.234B | 6.58 |
| Canopy Growth (CGC) | Canada | $0.228B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.226B | 0.00 |
| Omeros (OMER) | United States | $0.195B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.192B | 0.00 |
| Organigram Global (OGI) | Canada | $0.188B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 14.93 |
| Verano Holdings (VRNOF) | United States | $0.175B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.136B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 14.79 |
| Jin Medical (ZJYL) | China | $0.102B | 0.00 |
| Veru (VERU) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.089B | 11.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.085B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.083B | 0.00 |
| MacroGenics (MGNX) | United States | $0.080B | 0.00 |
| Zynex (ZYXI) | United States | $0.079B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.079B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 60.57 |
| United-Guardian (UG) | United States | $0.038B | 13.18 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Safety Shot (SHOT) | United States | $0.023B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |